# A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

> **NCT01358734** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 88 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Lenalidomide
- **OTHER:** Best Supportive Care (BSC)

## Key facts

- **NCT ID:** NCT01358734
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-27
- **Primary completion:** 2015-05-19
- **Final completion:** 2018-05-15
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2019-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01358734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01358734, "A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01358734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*